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Abstract  42 
Individuals with cold sensitivity have low peripheral skin blood flow and skin temperature 43 
possibly due to reduced nitric oxide (NO•) bioavailability. Beetroot has a high concentration 44 
of inorganic nitrate and may increase NO-mediated vasodilation. Using a placebo-controlled, 45 
double blind, randomised, crossover design, this study tested the hypotheses that acute 46 
beetroot supplementation would increase the rate of cutaneous rewarming following a local 47 
cold challenge and augment endothelium-dependent vasodilation in cold sensitive 48 
individuals.  49 
Thirteen cold sensitive participants completed foot and hand cooling (separately, in 15 °C 50 
water for 2 minutes) with spontaneous rewarming in 30°C air whilst skin temperature and 51 
cutaneous vascular conductance (CVC) were measured (Baseline). On two further separate 52 
visits, participants consumed 140 ml of either concentrated beetroot juice (nitrate 53 
supplementation) or nitrate-depleted beetroot juice (Placebo) 90 minutes before resting 54 
seated blood pressure was measured. Endothelial function was assessed by measuring CVC 55 
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at the forearm, finger and foot during iontophoresis of 1% w/v acetylcholine followed by foot 56 
and hand cooling as for Baseline. 57 
Plasma nitrite concentrations significantly increased in nitrate supplementation compared to 58 
Placebo and Baseline (502 ± 246 nmol.L-1; 73 ± 45 nmol.L-1; 74 ± 49 nmol.L-1 respectively; n=11; 59 
P < 0.001). Resting blood pressure and the response to foot and hand cooling did not differ 60 
between conditions (all P > 0.05). Nitrate supplementation did not alter endothelial function 61 
in the forearm, finger or foot (all P > 0.05) compared to Placebo.  62 
Despite a physiologically meaningful rise in plasma nitrite concentrations, acute nitrate 63 
supplementation does not alter extremity rewarming, endothelial function or blood pressure 64 
in individuals with cold sensitivity. 65 
 66 
1.0 Introduction 67 
Non-freezing cold injury (NFCI) is caused by prolonged exposure to cold, and often cold and 68 
wet, conditions. NFCI most commonly affects the feet, although the hands can also be 69 
affected (Eglin et al. 2013). Chronic NFCI, which may last for many years, is characterised (in 70 
variable combination and severity) by cold sensitivity, numbness, hyperhidrosis and 71 
persistent pain which can significantly affect an individual’s quality of life (Golden et al. 2013). 72 
NFCI has been reported in individuals following exposure to cold environments such as: 73 
mountaineering and hill walking (Imray et al., 2009), diving (Laden et al., 2007), cycling (Fraser 74 
and Loftus, 1979), in homeless individuals (Wrenn, 1991) and the elderly (Williams et al., 75 
2005) as well as in individuals working in cold environments, (Mills and Mills, 1993, 76 
Cattermole, 1999, Golden et al., 2013).   77 
Although severe NFCI can be debilitating, its pathophysiology is not fully understood and 78 
therefore a definitive diagnostic tool is not available (Eglin et al., 2013). Sub-clinical forms of 79 
NFCI have also been characterised in individuals frequently exposed to cold conditions for 80 
short durations during recreational activities such as windsurfing, surfing and open water 81 
swimming. These individuals are cold sensitive (their hands and feet are cooler than “normal” 82 
individuals and they take longer to rewarm following cold exposure) but are not considered 83 
to have a cold injury (Eglin, 2011). As with NFCI and primary Raynaud’s (Gardner–medwin et 84 
al., 2001, O'Reilly et al., 1992), this cold sensitivity is associated with a reduced basal skin 85 
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blood flow and a smaller increase in skin blood flow upon rewarming (Davey et al., 2013, Hope 86 
et al., 2014). The resultant cooler peripheral skin temperature will result in reduced skin 87 
oxygen tension (Sheffield et al., 1996, Montgomery and Horwitz, 1950) and may put these 88 
individuals at greater risk of cold injury on subsequent cold exposure (Cattermole, 1999).  89 
Animal models of NFCI have shown reduced levels of oxygen in the cooled tissues 90 
(Montgomery et al., 1954) and that NFCI may be associated with a pro oxidant state (Geng et 91 
al., 2015). Local cooling has been shown to inhibit endothelial nitric oxide synthase (eNOS) as 92 
well as increase noradrenaline release (Hodges et al., 2006). In addition, eNOS activity has 93 
been shown to be positively associated with temperature (Kellogg et al., 2008). Nitric oxide 94 
(NO•) is a known vasodilator and plays a fundamental role in the control of skin blood flow 95 
(Hodges et al., 2006, Minson et al., 2001). Moreover, NO• released from S-nitrosohemoglobin 96 
(Stamler et al., 1997) in hypoxic environments plays a key role in regulating the physiological 97 
oxygen gradient. We have previously shown that glyceryl trinitrate, a NO• donor, increases 98 
the rate of rewarming following foot cooling in individuals with cold sensitivity (Hope et al., 99 
2014). However, individuals develop a tolerance to GTN and show diminishing vasodilatory 100 
effects with chronic treatment (Needleman and Johnson, 1973). In addition, the deleterious 101 
side effects such as headaches (Hsi et al., 2005) suggests that organic nitrates are not optimal 102 
long-term therapies for individuals with cold sensitivity.   103 
Leafy green vegetables and particularly beetroot have a high concentration of inorganic 104 
nitrate (Bryan and Hord, 2010). These vegetables are thought to be beneficial to 105 
cardiovascular health due to their vasodilatory effects (Gilchrist et al., 2010) with recent 106 
reports suggesting that tolerance to inorganic nitrate does not occur (as inferred by blood 107 
pressure responses) for at least 28 days (Thompson et al., 2017). Inorganic nitrate can act as 108 
a source of systemic NO• generation (Lundberg and Govoni, 2004). Briefly, inorganic nitrate 109 
is converted to nitrite by facultative anaerobic bacteria on the dorsum of the tongue (Duncan 110 
et al., 1995) with small quantities of this nitrite being converted to NO• and other nitrogen 111 
oxides such as S-Nitrosothiols (RSNO) by the acidic environment of the stomach (Benjamin et 112 
al., 1994). The remaining nitrite and RSNO are then absorbed into the circulation where they 113 
act as a storage pool for subsequent NO• production (Lundberg and Weitzberg, 2005), which 114 
is expedited in hypoxaemia (Cosby et al., 2003), such as that observed in cold sensitivity 115 
(Davey et al., 2013, Montgomery and Horwitz, 1950, Sheffield et al., 1996, Hope et al., 2014). 116 
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This enterosalivary pathway and its purported therapeutic effects have been reviewed 117 
elsewhere (Lundberg et al., 2008). Inorganic nitrate, in the form of beetroot juice, improves 118 
skin blood flow (Levitt et al., 2015), microvascular function (Keen et al., 2014) and lowers 119 
blood pressure (BP) in healthy individuals (Webb et al., 2008) and in individuals with 120 
hypertension (Kapil et al., 2015) and peripheral arterial disease (Kenjale et al., 2011). In 121 
contrast, some studies have shown no effect of nitrate supplementation on vascular health 122 
markers despite increases in circulating NO• intermediates in healthy (Bahra et al., 2012, 123 
Shepherd et al., 2016) and clinical populations (Gilchrist et al., 2013). However, the potential 124 
for beetroot juice to offer an inexpensive, safe and potentially effective intervention to 125 
improve peripheral circulation in individuals with cold sensitivity has not been studied. 126 
Recently, nitrate supplementation has also been shown to lower sympathetic nerve activity 127 
(Notay et al., 2017)  and nitrate/nitrite has been shown to restore vascular function when 128 
NOS is inhibited (Ferguson et al., 2016, Carlström et al., 2010). Therefore, as cold sensitive 129 
individuals exhibit impaired vascular function possibly due to lower eNOS activity and 130 
increased sympathetic drive, nitrate supplementation, and the associated increase in the 131 
circulating NO• pool, might help alleviate the associated detrimental effects as shown with 132 
organic nitrates (Hope et al., 2014, Anderson et al., 2002).  133 
We hypothesised that compared to baseline and placebo, nitrate supplementation would 134 
increase plasma nitrite concentration, the rate of cutaneous rewarming following a local cold 135 
challenge and augment endothelium-dependant vasodilation in individuals with cold 136 
sensitivity. 137 
 138 
2.0 Methods  139 
All procedures for this randomised placebo-controlled, double-blind, cross-over designed trial 140 
were approved by the University of Portsmouth Science Faculty Research Ethics committee 141 
(2016-107A) and all volunteers provided written informed consent prior to participation. All 142 
testing took place at the Department of Sport and Exercise Science, University of Portsmouth 143 
between January and March 2017 when the outdoor air temperature averaged 5.8 ± 2.9°C at 144 
the time of testing (range 0°C to 10°C). 145 
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2.1 Participants 146 
Participants were recruited based on their self-reported frequent exposure to cold 147 
environments (e.g. winter sea swimming, sailing etc.) or often having cold hands and feet. A 148 
baseline cold sensitivity test (described below) was conducted to determine whether the 149 
participants had cold sensitive feet or hands. This was defined as a toe or finger skin 150 
temperature less than 32°C prior to the cold water immersion and after 5 minutes of 151 
rewarming in 30°C air (House et al., 2015, Eglin et al., 2013). Exclusion criteria included; 152 
diagnosis of a prior freezing injury, peripheral vascular disease, thalassaemias affecting 153 
haemoglobin and / or hepatitis B.  154 
All participants were non-smokers (for at least 1 year). Participants refrained from consuming 155 
food high in nitrate the day before testing and were asked to keep a food diary for the 24 156 
hours before their first visit to the laboratory and to replicate this prior to each visit. 157 
Participants abstained from alcohol for 24 hours and caffeine for 3 hours prior to testing. The 158 
participants also refrained from using any antibacterial mouth wash for 7 days prior to each 159 
test as this has been shown to reduce the concentration of oral bacterial that are responsible 160 
for the reduction of nitrate to nitrite (Govoni et al., 2008). Female volunteers were asked 161 
about their menstrual cycle to determine whether they were in the follicular or luteal phase 162 
or whether they were peri- or post-menopausal. However, the phase of the menstrual cycle 163 
was not controlled for since reproductive hormone status does not affect the responses to 164 
local cooling (Lunt and Tipton, 2014), thermal perception (Lunt and Tipton, 2014) or 165 
iontophoresis of acetylcholine (Ketel et al., 2009). 166 
2.2 Protocol 167 
The participants attended the laboratory on three separate occasions at the same time of day 168 
to reduce any circadian effects. On arrival at the laboratory, resting seated blood pressure 169 
was measured using an automated blood pressure monitor (Omron HEM-705C, Omron, 170 
Milton Keynes, UK) with the average of the final three measurements from the brachial artery 171 
being recorded and used to calculate mean arterial pressure (MAP). On the first visit 172 
(Baseline) the participants then undertook a cold sensitivity test (see below) and if they were 173 
classified as cold sensitive, a venous blood sample was taken for measurement of plasma 174 
7 
 
nitrate and nitrite using the ozone chemiluminescence technique (Sievers NOA 280; Analytix 175 
Ltd, Durham, UK) using a protocol adapted from Bateman et al. (2002). 176 
One and a half hours before arriving at the laboratory for the second and third visit, which 177 
were separated by a wash-out period of at least 7 days, the participants consumed either 140 178 
ml of concentrated beetroot juice (nitrate supplementation; 11.9 mmol nitrate; Beet it, James 179 
White Drinks Ltd., Ashbocking, UK) or nitrate-depleted concentrated beetroot juice as a 180 
placebo (Placebo; 0.02 mmol nitrate; Beet it, James White Drinks Ltd., Ashbocking, UK). This 181 
dose has been used in previous studies (Shepherd et al., 2016) and results in peak nitrite 182 
concentrations between two and three hours (Wylie et al., 2013) coinciding with the testing. 183 
The placebo was similar to the nitrate-rich beetroot juice in taste, colour, texture, 184 
appearance, odour and packaging (Gilchrist et al., 2014). On arrival at the laboratory the 185 
participants’ blood pressure was measured, as described above, and a venous blood sample 186 
was taken for measurement of plasma nitrate and nitrite. Following this, participants 187 
undertook an endothelium function test followed by a cold sensitivity test of their foot and 188 
hand (both described below).  189 
2.3 Cold sensitivity test 190 
The cold sensitivity test used in this study has been described in detail elsewhere (Eglin et al., 191 
2013, Hope et al., 2014). Participants entered a climatic chamber controlled at an air 192 
temperature of 30.3 (0.4) °C, removed their shoes and socks, and rested in a semi- recumbent 193 
position for 15 minutes. They then exercised on a cycle ergometer (874E, Monark, Sweden) 194 
for 12 minutes at an external work rate of 50 W (previously shown to improve the reliability 195 
of the test, (Eglin et al., 2013). Following the 12 minutes cycling, the participant then rested 196 
in a semi-recumbent position for 5 minutes whilst resting toe skin temperature and blood 197 
flow were recorded. 198 
The participant’s left foot was then placed in a plastic bag and immersed in a water bath 199 
stirred and maintained at 15.1 ± 0.2 °C to the point of their mid-malleoli for 2 minutes.  After 200 
the immersion period, the plastic bag was removed and rewarming monitored for 10 minutes 201 
whilst the participant remained resting in a semi-recumbent position.  202 
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The participant then rested in a seated position for 5 minutes whilst finger skin temperature 203 
and blood flow was recorded. The participant, still seated, placed their left hand in a plastic 204 
bag and immersed it to the level of the wrist in water at 15.0 ± 0.2 °C for 2 minutes. After the 205 
immersion period, the plastic bag was removed and rewarming monitored for 10 minutes 206 
whilst the participant remained resting in a seated position with their arm supported by an 207 
arm rest.   208 
2.3.1 Measurements 209 
Skin blood flow was measured using a laser Doppler probe (VP1T / 7, Moor Instruments, UK) 210 
placed on the Great toe pads during foot immersion and on the pads of the thumbs during 211 
hand immersion. Skin blood flow was analysed using minute averages before, during and after 212 
immersion (rewarm period) and expressed as cutaneous vascular conductance (CVC = skin 213 
flux/MAP; flux.mmHg-1). CVC was analysed between conditions at the following time points: 214 
pre immersion, 5 and 10 min of rewarming. 215 
Skin temperature was measured using an infrared camera (A320G, FLIR systems, UK) 216 
according to the guidelines described in (Moreira et al., 2017). The camera was positioned 1.0 217 
m away from the sole of the foot and 0.7 m away from the palm of the hand and recorded 218 
using the spot analysis function on the FLIR software (FLIR systems, UK) prior to immersion 219 
and every minute during the 10 minute rewarming periods. Great toe, coldest toe, mean toe, 220 
thumb and mean finger skin temperature were analysed between conditions at the following 221 
time points: pre immersion, 5 and 10 min of rewarming. The coefficient of variation in our 222 
laboratory for the cold sensitivity test is 2.7% for the finger skin temperatures and 8.7% for 223 
the toe skin temperatures (unpublished data, n=13).  224 
Blood pressure was measured on the right arm prior to foot and hand immersion and at the 225 
end of both rewarming periods using an automated blood pressure monitor (Omron HEM-226 
705C, Omron, Milton Keynes, UK) for calculation of MAP.  227 
Thermal sensation and comfort were measured using 20 cm scales (0 = very 228 
cold/uncomfortable; 10 = neutral; 20 = very hot/comfortable; modified from Zhang et al. 229 
(2004)) and recorded prior to immersion, during immersion and every 2 minutes of the 230 
rewarming period. Pain sensation was recorded using a subjective numerical rating scale 231 
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(NRS) for pain (0 no pain, 10 unimaginable, unspeakable pain; (Ferreira-Valente et al., 2011)) 232 
at the same time points.  233 
2.4 Endothelium function test 234 
Following an acclimation period of at least 20 minutes, acetylcholine (ACh) was delivered 235 
transdermally using iontophoresis to three sites in the following order: volar aspect of the left 236 
forearm, middle phalanx of the middle finger of the left hand and dorsal aspect of the left 237 
foot as previously described (Maley et al. 2017). Briefly, a perspex ring containing the anode 238 
was attached to the skin site with the cathode attached using a gel pad at the wrist or ankle. 239 
Both electrodes were connected to a battery powered iontophoresis controller (MIC 2, Moor 240 
Instruments, UK). The anode chamber (8 mm inner diameter) was filled with approximately 241 
0.5 mL of ACh. ACh was dissolved into sterile water for injection (Braun, Melsungen, Germany) 242 
to yield a concentration of 1%. The protocol consisted of eight pulses: four pulses of 25 μA 243 
followed by a single pulse of 50 μA, 100 μA, 150 µA and a final pulse of 200 µA applied for 20 244 
seconds with 60 second intervals between each pulse where no current was applied. After an 245 
interval of 5 minutes the protocol was repeated on the next skin site. The tests were 246 
conducted at a room temperature of 23.2 (0.4) °C. 247 
2.4.1 Measurements 248 
Skin blood flow was measured using a laser Doppler probe (VP1T / 7, Moor Instruments, UK) 249 
connected to a laser Doppler perfusion monitor (moor VMS-LDF, Moor Instruments, UK). Flux 250 
data from the laser Doppler and iontophoresis controller was recorded using a data 251 
acquisition system and software (Powerlab and LabChart 7, AD Instruments, Australia). The 252 
laser Doppler probe was placed into the perspex ring used for iontophoresis on the forearm, 253 
finger, dorsal foot and on the corresponding site on the contra-lateral limb. Skin blood flow 254 
responses were expressed as CVC.  255 
Average skin blood flow in response to iontophoresis of ACh was calculated over the final 20 256 
seconds of the interval between successive pulses and between 40 to 60 seconds after the 257 
final pulse (Maley et al., 2017). These responses were expressed as absolute CVC as baseline 258 
CVC did not differ between conditions for any site. ED50, expressed as 95 % confidence 259 
intervals, was calculated using GraphPad (Version 5, USA). Maximum skin blood flow and area 260 
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under the curve (AUC) were calculated for each participant. The point at which the skin blood 261 
flow was at a maximum point was not always identified following the final pulse therefore 262 
maximum skin blood flow was taken from wherever it was highest. Skin temperature was 263 
measured adjacent to the iontophoresis site using a skin thermistor (Grants Instruments, 264 
Cambridge) and recorded on a data logger (Grants Instruments, Cambridge). Blood pressure 265 
was measured on the contralateral arm to iontophoresis using an automated blood pressure 266 
monitor (Omron HEM-705C, Omron, Milton Keynes, UK) before and after each ACh dose 267 
response curve for calculation of MAP.  268 
2.5 Sample size and randomisation 269 
An a priori sample size calculation was performed based on data from our previous study on 270 
the effect of GTN in cold sensitive individuals (Hope et al. 2013) which showed a 4.2 ± 3.0 °C 271 
change in skin temperature 10 minutes post immersion during the cold sensitivity test. For 272 
90% power and an α-level of 5% (two tailed) it was calculated that 13 participants were 273 
required.  274 
A computer programme generated a random sequence that was used to assign each 275 
participant to begin the trial in one of two arms. Participants were then supplied with the 276 
requisite juice (in a sealed, opaque envelope prepared by individuals not involved in the trial) 277 
which was counter-balanced and blinded from the participants and researchers.  278 
2.6 Data analysis  279 
As with other studies using this technique (Maley et al., 2017) some individuals had high skin 280 
resistance which meant that it was not possible to deliver all of the current pulses in each skin 281 
site for all participants. Therefore, only those who were able to receive the first pulse of 282 
iontophoresis were included in analyses. Where an incomplete current response curve was 283 
delivered (due to high skin resistance at the higher currents), the number of pulses used in 284 
the analysis was the same within individual for both conditions. A blood sample was not 285 
obtained from two participants due to technical difficulties and therefore n=11 for Baseline 286 
and n=12 for Placebo and nitrate supplementation for plasma nitrate and nitrite 287 
concentrations.  288 
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 Assumption of normal distribution of data was assessed using descriptive methods 289 
(skewness, outliers, and distribution plots) and inferential statistics (Shapiro–Wilk test). 290 
Where normality was not met, nonparametric tests were performed. For the cold sensitivity 291 
test, statistical differences were assessed using repeated measures ANOVAs (condition 292 
[Baseline, Placebo, nitrate supplementation] * time [pre immersion, 5 min, 10 min]) for toe 293 
skin temperatures, thumb and Great toe skin blood flows. Finger skin temperatures, thermal 294 
comfort, thermal sensation and pain were analysed using Friedman tests. For the endothelial 295 
function test, maximum CVC, AUC and skin temperature were analysed using ANOVAs 296 
(condition [Baseline, Placebo, nitrate supplementation] * skin site [forearm, finger, foot]). 297 
ED50 values were analysed using paired samples t-test.  Plasma nitrate and nitrite 298 
concentrations were analysed using a one way ANOVA. Where appropriate, post-hoc tests 299 
were conducted using pairwise comparisons with Bonferroni corrections. Data are presented 300 
as mean (SD), unless otherwise stated. Statistical analysis was performed on SPSS version 22 301 
(Chicago, IL) and statistical difference was accepted as P < 0.05. 302 
3.0 Results   303 
Twenty volunteers (10 women, 10 men) gave written informed consent to participate in this 304 
trial. Following the baseline cold sensitivity test, 6 individuals (5 women, 1 man; age 25.8 ± 305 
4.2 y; height 1.71 ± 0.13 m; body mass 77.7 ± 17.7 kg) were withdrawn from the trial as they 306 
did not meet the skin temperature requirements to be classified as cold sensitive (House et 307 
al., 2015) (Figure 1). Fourteen individuals (Figure 1a) were randomised to start in either the 308 
nitrate supplementation arm or the placebo arm. One individual was subsequently withdrawn 309 
following randomisation (nitrate supplementation first, placebo second) due to use of 310 
mouthwash during the intervention period. Therefore, thirteen cold sensitive individuals 311 
completed the study (4 women, 9 men; age 34.5 ± 13.2 y; height 1.77 ± 0.07 m; body mass 312 
85.0 ± 15.9 kg). Consistent with our previous findings (Shepherd et al., 2016) the beetroot 313 
juice was well tolerated and no adverse events (other than beeturia and discoloured stools) 314 
were reported, neither could the participants identify whether they had ingested the placebo 315 
or beetroot juice.  316 
 317 
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Figure 1A 319 
 320 
Figure 1B 321 
Figure 1. Participant flow through the trial (A) and average (SD) mean toe skin temperature 322 
during the Baseline cold sensitivity test in individuals with (n=13) and without cold sensitivity 323 
(n=6) (B). The dotted line represents the cut off skin temperature (Tsk) pre-immersion (-2 324 
minutes) and at 5 minutes of rewarming used for determining cold sensitivity.   325 
4.1 Plasma nitrate and nitrite concentrations 326 
There was a statistically significant rise in plasma nitrate (Baseline, 53.1 ± 29.4 µM; Placebo, 327 
50.5 ± 24.3 µM; nitrate supplementation, 756.8 ± 175.2 µM; F(2, 20) = 198.1, P < 0.001) and 328 
nitrite (Baseline, 73.7 ± 48.8 nM; Placebo, 73.5 ± 44.5 nM; nitrate supplementation, 501.5 ± 329 
245.8 nM; F(2, 20) = 33.6, P < 0.001) following nitrate supplementation when compared to 330 
Placebo and Baseline (Figure 2).  331 
 332 
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 333 
Figure 2. Mean (SD) and individual plasma nitrate (A) and nitrite (B) concentrations in the 334 
Baseline, Placebo and nitrate supplementation conditions (n=11). * P < 0.001 significantly 335 
different from Placebo and Baseline.  336 
 337 
4.2 Cold sensitivity test  338 
There was no effect of nitrate supplementation on skin blood flow in the Great toe (F (2, 24) = 339 
1.31, P = 0.289), or thumb (F (2, 24) = 0.42, P = 0.660; Figure 3) when compared to Placebo or 340 
Baseline.  341 
Skin blood flow was significantly different across time for the Great toe (F (2, 24) = 6.79, P = 342 
0.005) with a lower CVC observed at 5 min rewarming compared to pre-immersion (P = 0.002; 343 
Figure 3A). Thumb skin blood flow also differed across time (F (2, 24) = 9.39, P = 0.001) with CVC 344 
being lower at 5 and 10 min of rewarming compared to pre-immersion (P = 0.025 and P = 345 
0.016 respectively; Figure 3C). 346 
There was no interaction between time and condition for skin blood flow in either the Great 347 
toe (F (4, 48) = 1.58, P = 0.195) or thumb (F (4, 48) = 0.62, P = 0.650) when nitrate supplementation 348 
was compared to Placebo and Baseline (Figure 3 and Table 1).  349 
There was no effect of nitrate supplementation on skin temperature of the Great toe (F (2, 24) 350 
= 0.70, P = 0.51), coldest toe (F (2, 24) = 0.81, P = 0.46), mean toe (F (2, 24) = 0.61, P = 0.55), or 351 
mean finger (pre immersion: X2 (2) = 2.57, P = 0.27, 5 minutes rewarming: X2 (2) = 2.63, P = 0.27, 352 
or 10 minutes rewarming: X2 (2) = 2.47, P = 0.29).  353 
Skin temperature was significantly different across time for the Great toe (F (2, 24) = 14.8, P < 354 
0.001), coldest toe (F (2, 24) = 18.8, P < 0.001) and mean toe (F (2, 24) = 35.2, P < 0.001). Skin 355 
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temperature after 5 minutes of rewarming was colder than pre immersion (P = 0.028; P = 356 
0.001 P < 0.001 respectively) but had returned to pre-immersion temperatures after 10 357 
minutes (P = 0.318; P = 1.00; P = 1.00 respectively).  358 
There was no interaction between time and condition for skin temperature (Great toe: F (4, 48) 359 
= 1.60, P = 0.19; coldest toe F (4, 48) = 1.81, P = 0.14; mean toe F (4, 48) = 0.81, P = 0.52) when 360 
nitrate supplementation was compared to Placebo and Baseline (Figure 3 and Table 1). 361 
  362 
Figure 3. Skin blood flow and temperature during the cold sensitivity test of the foot and hand 363 
in the Baseline, Placebo and nitrate supplementation conditions. Mean (SD) cutaneous 364 
vascular conductance (CVC) in the Great toe (A) and thumb (B) and skin temperature (Tsk) in 365 
the Great toe (C) and thumb (D) are shown  (n = 13). 366 
 367 
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 372 
Table 1. Mean (SD) toe, coldest toe and mean finger skin temperature (Tsk) during the cold 373 
sensitivity test in the Baseline, Placebo and nitrate supplementation conditions (n = 13). 374 
 
          
 
    Rewarming  
     Pre immersion    5 minutes 10 minutes 
 
 
Mean toe T
sk  
(°C) 
Baseline 29.4 ± 2.4 27.2 ± 2.3 29.6 ± 3.1 
 
 Placebo 30.0 ± 3.2 28.7 ± 4.0 30.3 ± 3.9 
 
 
Nitrate supplementation 30.8 ± 3.5 29.0 ± 3.7 30.7 ± 3.4 
 
 Coldest toe Tsk 
(°C) 
Baseline 28.2 ± 2.3 25.8 ± 1.9 28.5 ± 3.2 
 
 
Placebo 28.6 ± 3.3 27.6 ± 4.2 29.2 ± 4.2 
 
 
Nitrate supplementation 29.6 ± 3.6 28.1 ± 3.4 29.6 ± 3.4 
 
 Mean finger T
sk 
(°C) 
Baseline 34.3 ± 1.7 33.1 ± 3.3 33.0 ± 3.0 
 
 
Placebo 34.6 ± 1.4 33.2 ± 3.1 33.6 ± 2.3 
 
 Nitrate supplementation 34.5 ± 1.2 33.7 ± 1.8 34.0 ± 1.9 
 
   
     
There were no differences in thermal sensation, thermal comfort or pain votes at any time 375 
point during the cold sensitivity test between conditions (Table 2). 376 
 377 
 378 
 379 
 380 
 381 
 382 
 383 
 384 
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Table. 2. Thermal sensation, thermal comfort and pain in the foot and hand during the cold 385 
sensitivity test in the Baseline, Placebo and nitrate supplementation conditions (n=13). 386 
Average rewarm is the mean vote over the last 8 minutes of rewarming. 387 
 388 
4.3 Endothelial function 389 
Skin temperature during ACh iontophoresis was similar in both the Placebo and nitrate 390 
supplementation conditions (F (1, 11) = 0.30, P = 0.59; F (2, 22) = 0.54, P = 0.58; Table 3). As 391 
   
      
 
  
Condition  
Pre 
immersion 
During 
immersion 
Immediately 
after immersion 
Average rewarm 
 
Foot 
Thermal  
sensation  
Baseline 12.0 ± 2.2 4.9 ± 2.0 6.8 ± 2.7 10.0 ± 2.1 
 
Placebo 12.2 ± 2.5 4.5 ± 1.5 6.3 ± 1.9 10.3 ± 1.9 
 
Nitrate supplementation 13.3 ± 2.1 4.8 ± 1.9 6.5 ± 1.7 10.0 ± 1.4 
 
Thermal  
comfort 
Baseline 14.7 ± 1.9 9.5 ± 4.6 10.9 ± 4.4 13.1 ± 2.9 
 
Placebo 13.4 ± 3.3 8.5 ± 3.0 10.9 ± 4.1 13.6 ± 3.1 
 
Nitrate supplementation 13.4 ± 3.7 8.5 ± 3.8 9.9 ± 3.8 12.8 ± 3.0 
 
Pain 
Baseline 0.8 ± 1.0 0.4 ± 0.7 0.1 ± 0.3 0 ± 0 
 
Placebo 0.5 ± 0.8 0.2 ± 0.6 0 ± 0 0 ± 0 
 
Nitrate supplementation 0.9 ± 1.1 0.5 ± 0.8 0.1 ± 0.3 0 ± 0 
 
Hand 
Thermal  
sensation  
Baseline 12.7 ± 2.4  4.5 ± 1.6 6.3 ± 2.9 11.0 ± 2.7 
 
Placebo 12.7 ± 2.0 4.4 ± 1.5 5.9 ± 1.9 11.0 ± 2.1 
 
Nitrate supplementation 11.8 ± 2.0 5.2 ± 1.8 6.5 ± 2.4 11.5 ± 2.1 
 
Thermal  
comfort 
Baseline 14.6 ± 2.3 7.8 ± 3.8 8.5 ± 4.6 12.8 ± 2.3 
 
Placebo 14.0 ± 3.2 8.7 ± 3.7 10.3 ± 4.0 13.5 ± 3.0 
 
Nitrate supplementation 14.3 ± 3.1 7.9 ± 3.9 9.7 ± 4.1 13.2 ± 2.5 
 
Pain 
Baseline 0.9 ± 0.9 0.7 ± 0.9 0.1 ± 0.3 0 ± 0 
 
Placebo 0.9 ± 1.2 0.3 ± 0.6 0.0 ± 0.8 0 ± 0 
 
Nitrate supplementation 0.8 ± 1.1 0.5 ± 1.0 0.1 ± 0.3 0 ± 0 
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expected skin temperature was different between skin sites, with the foot being 3.6°C colder 392 
than the forearm and 2.6°C colder than the finger (F (2, 22) = 14.7, P < 0.001; Table 3). 393 
Average CVC prior to iontophoresis was similar between conditions, for the forearm (n=12, 394 
0.13 ± 0.08 flux.mmHg-1, P = 0.59), the finger (n=12, 0.66 ± 0.53 flux.mmHg-1, P = 0.60) and 395 
the foot (n = 13, 0.13 ± 0.09 flux.mmHg-1, P = 0.99). There was no effect of nitrate 396 
supplementation on the vasodilatory dose response to transdermal delivery of ACh in the 397 
forearm, finger or foot (Figure 4). Maximum skin blood flow (F (1, 11) = 0.01, P = 0.92) and AUC 398 
(F (1, 11) = 0.32, P = 0.59) were similar between Placebo and nitrate supplementation (Table 3) 399 
and no significant interactions were observed (maximum blood flow: F (2, 22) = 1.84, P = 0.18; 400 
AUC: F (2, 22) = 0.66, P = 0.53). No differences were seen in ED50 for the forearm (P = 0.63), 401 
finger (P = 0.62) or foot (P = 0.30) between Placebo and nitrate supplementation (Table 3). 402 
However there was a difference between skin sites in the magnitude of the vasodilation to 403 
ACh (maximum skin blood flow: F (2, 22) = 19.7, P < 0.001; AUC: F (2, 22) = 14.3, P < 0.001; Figure 404 
4 and Table 3).  405 
Table 3. Skin blood flow response to iontophoresis of ACh on the forearm, finger and foot in 406 
the Placebo and nitrate supplementation conditions. Data are given as mean ± SD for 407 
maximum CVC, area under the curve (AUC) and skin temperature (Tsk) and 95% confidence 408 
intervals are given for the ED50. 409 
        
    n Maximum (CVC) ED50 (µA) AUC Tsk (°C) 
 
Forearm 
Placebo 13 2.0 ± 1.0 75.9 to 118.8 9.6 ± 7.2 30.2 ± 1.2 
 
Nitrate supplementation 13 2.3 ± 0.7 69.2 to 111.1 10.6 ± 5.3 30.1 ± 1.0 
 
Finger 
Placebo 12 3.3 ± 1.6 73.4 to 109.3 16.8 ± 11.1 29.5 ± 3.3 
 
Nitrate supplementation 12 3.1 ± 1.5 67.3 to 102.8 15.1 ± 9.3 28.8 ± 3.3 
 
Foot 
Placebo 13 1.2 ± 0.8 105.0 to 147.6 4.7 ± 3.1 26.5 ± 1.9 
 
Nitrate supplementation 13 1.0 ± 0.7  119.3 to 167.7 4.0 ± 2.8  26.6 ± 2.0 
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 410 
 411 
Figure 4. Cutaneous vascular conductance following iontophoresis of ACh on the forearm (A), 412 
finger (B) and foot (C) in the Placebo and nitrate supplementation conditions (n = 13 413 
participants), for finger CVC, n = 12 at cumulative current 400 and 600 µA).  414 
4.4 Resting blood pressure 415 
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There was no effect of nitrate supplementation on systolic blood pressure (Baseline, 123 ± 12 416 
mmHg, Placebo 121 ± 9 mmHg, nitrate supplementation 124 ± 13 mmHg; F (2, 22) = 0.87, P = 417 
0.43), diastolic blood pressure (Baseline, 79 ± 10 mmHg, Placebo 74 ± 10 mmHg, nitrate 418 
supplementation 76 ± 11 mmHg; F (2, 22) = 2.81, P = 0.08) or mean arterial blood pressure 419 
(Baseline, 94 ± 11 mmHg, Placebo 90 ± 9 mmHg, nitrate supplementation 92 ± 11 mmHg; F (2, 420 
22) = 2.29, P = 0.13) when compared to Placebo and Baseline.  421 
5.0 Discussion  422 
This is the first study to examine the effects of nitrate supplementation in the form of 423 
concentrated beetroot juice on extremity rewarming following a cold stimulus in individuals 424 
with cold sensitivity. Contrary to our hypotheses, acute nitrate supplementation did not alter 425 
extremity rewarming, endothelial function, blood pressure, pain or thermal comfort and 426 
sensation. This was despite a physiologically meaningful rise in plasma nitrite concentrations 427 
in the nitrate supplementation condition (Figure 2).  428 
Plasma nitrate and nitrite increased by 703.6 µM and 423.5 nM respectively following 429 
ingestion of beetroot juice containing 11.9 mmol of nitrate. This change from baseline in 430 
plasma nitrite concentration following nitrate supplementation is similar to that reported in 431 
other studies with similar supplementation regimes such as Webb et al. (2008) and Wylie et 432 
al. (2013) who report changes of 180 nM and 395 nM respectivley. We would note that due 433 
to our protocol design (venous blood samples were taken 1.5 hours post ingestion which is 434 
approximately 1 hour prior to peak plasma nitrate and nitrite concentrations (Wylie et al., 435 
2013)) we cannot preclude that nitrate and nitrate values maybe higher than what we have 436 
reported. This was done in order to enable the primary outcomes to be measured at the time 437 
of peak plasma nitrite concentration.  438 
There was no effect of nitrate supplementation on peripheral blood flow and skin 439 
temperature following exposure to a cold stimulus when compared to Placebo or Baseline 440 
(Figure 3 and Table 1). As a consequence nitrate supplementation did not improve thermal 441 
sensation, thermal comfort or reduce the associated pain with the cold stimulus when 442 
compared to Placebo or Baseline (Table 2). These findings were in contrast to our previous 443 
study which showed that organic nitrate (GTN spray) increased peripheral blood flow and skin 444 
temperature in drug naive individuals with cold sensitivity (Hope et al., 2014). The disparity 445 
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between the findings in our two studies is likely due to any combination of the differences 446 
between inorganic nitrate and organic nitrates, such as their pharmacokinetics, 447 
pharmacodynamics and bio-activation (Janero et al., 2004, Gilchrist et al., 2011, Omar et al., 448 
2012). Elucidating which of these differences were responsible for the lack of effect in 449 
peripheral blood flow in the current study requires further investigation. Irrespective of which 450 
of these differences are responsible for the lack of effect seen in this trial, it is difficult to 451 
compare organic and inorganic nitrates as NO• donors. For instance, 80-90% of GTN is 452 
metabolised by liver (Münzel et al., 2005) whereas, the oral microflora within the mouth are 453 
an essential component for the processing of inorganic nitrite production and subsequent 454 
NO• production (Duncan et al., 1995). These differences, among others are reviewed 455 
elsewhere by Münzel et al. (2005) and Omar et al. (2012).  456 
Elevations in reactive oxygen species have been shown in rat models of NFCI (Geng et al., 457 
2015) but have yet to be shown in individuals with cold sensitivity. However, individuals with 458 
cold sensitivity have significantly impaired microvasculature (see Figure 1 for comparison to 459 
the “normal” response) and therefore redox balance may be altered in favour of a pro-oxidant 460 
state (Bertuglia and Giusti, 2003). This would result in a reduced bioavailability of NO•, 461 
principally via uncoupling of endothelial nitric oxide synthase and reduction of 462 
tetrahydrobiopterin (Landmesser et al., 2003) which leads to an increase of superoxide’s and 463 
peroxynitrite. Further research is required to determine whether this sub-clinical population 464 
have elevated levels of oxidative stress and whether chronic, rather than acute, beetroot juice 465 
supplementation would alter this redox balance thus restoring endothelial function. As 466 
individuals with cold sensitivity have cooler extremities they are likely to have diminished 467 
eNOS activity reducing NO• production (Kellogg et al., 2008). Longer term nitrate 468 
supplementation may alleviate these reductions in the NO• pool. Moreover, recent data have 469 
shown that nitrate supplementation may reduce sympathetic nervous activity (Notay et al., 470 
2017) which may also be beneficial to individuals with cold sensitivity.   471 
Skin blood flow and temperature were lower in the toes than fingers during the cold 472 
sensitivity test (Figure 3; Table 1) and whilst all participants had cold sensitive feet, only one 473 
participant had cold sensitive hands. This is despite their self-reported cold exposures to 474 
involve the hands and feet to similar degrees. This supports a recent study which reported a 475 
heterogeneous response of the hands and feet to a cold challenge (Norrbrand et al., 2017) 476 
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and that the feet appear to be more susceptible to cold injury than the hands (DeGroot et al., 477 
2003, Golden et al., 2013).  478 
There was no effect of nitrate supplementation on the skin blood flow response to 479 
transdermal delivery of ACh in the forearm, finger or foot when compared to Placebo. A 480 
previous study in patients with type 2 diabetes also showed no effect of nitrate 481 
supplementation on the response to ACh (Gilchrist et al. 2013). Other studies have reported 482 
nitrate supplementation resulted in an increase in CVC in the response to local (Keen et al., 483 
2014) and whole body (Levitt et al., 2015) heating in healthy individuals. The increase in CVC 484 
in these two studies was a function of a decreased MAP since raw flux data was not altered 485 
by nitrate supplementation, as in the current study. Differences in nitrate supplementation 486 
regime (a 3 day [~5 mmol/day] supplementation vs an acute dose 1.5 hours [~12 mmol] prior 487 
to testing) and the lack of a placebo in the other studies could explain the lack of effect of 488 
nitrate supplementation on MAP in the current study. It is possible that a longer 489 
supplementation period may augment ACh-induced vasodilation in the peripheral 490 
microvasculature. This study was designed to have peak plasma nitrite concentrations (~3 491 
hours post ingestion) during our primary outcome testing (cold sensitivity test) which means 492 
that the iontophoresis (endothelial function test) was likely to have been conducted at lower 493 
concentrations of plasma nitrite. We therefore, cannot exclude that, if the iontophoresis was 494 
conducted at peak plasma nitrite concentrations that nitrate supplementation could have 495 
been beneficial.   496 
There was no difference in systolic, diastolic or mean arterial BP following acute nitrate 497 
supplementation compared to Baseline or Placebo. Studies investigating short term nitrate 498 
supplementation and its effects on blood pressure in clinical populations with endothelial 499 
dysfunction have resulted in conflicting reports. For example, reductions in systolic blood 500 
pressure have been shown in individuals with chronic obstructive pulmonary disease (COPD) 501 
(Berry et al., 2014, Leong et al., 2015, Kerley et al., 2015) and hypertension (Kapil et al., 2015) 502 
whilst in contrast, other studies have found no effect in individuals with COPD (Shepherd et 503 
al., 2015b, Curtis et al., 2014), type 2 diabetes (Gilchrist et al., 2013, Shepherd et al., 2015a) 504 
and heart failure (Zamani et al., 2015). Differences between these studies include, dosing 505 
strategies (~5 vs ~12 mmol), timing of the supplement (ranging from 1.5 hours to 4 days which 506 
may affect peak plasma nitrite concentrations (Leong et al., 2015)) and importantly, some 507 
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studies did not include a true placebo (Berry et al., 2014, Kerley et al., 2015). Peak plasma 508 
nitrite and corresponding BP reductions typically occur at 2.5 to 4 hours post nitrate ingestion 509 
(Wylie et al., 2013). We measured BP indices at 1.5 hours post ingestion for pragmatic 510 
reasons, therefore we are likely to have missed the peak in plasma nitrite concentration and 511 
cannot exclude that the lack of effect on BP maybe due to timing. Larger, well controlled 512 
studies are needed in clinical cohorts to elucidate if any clinically meaningful benefits of short 513 
term dietary nitrate supplementation exist as the evidence to date is equivocal.  514 
The main strength to this study is the rigorous experimental design (a double blind, placebo 515 
controlled, crossover, randomised control trial). As the current study examined acute 516 
supplementation, future research should explore the potential benefits of longer 517 
supplementation periods and examine if increasing the bioavailability of nitric oxide could 518 
improve endothelial function and microvascular responses to a cold challenge in individuals 519 
with impaired peripheral blood flow (e.g. non-freezing cold injury, Raynaud’s phenomenon 520 
and Scleroderma). A limitation to this study is that we did not measure change in redox 521 
balance. Antioxidants and polyphenols in the beetroot juice have the potential to alter NOx 522 
bioavailability. Given that the antioxidant and polyphenol content are the same for the nitrate 523 
enriched (nitrate supplementation) and depleted (Placebo) beetroot juices (Shepherd et al., 524 
2015a) and that we showed no difference between baseline, placebo or nitrate 525 
supplementation conditions for any variable, it is unlikely that the acute consumption of 526 
beetroot and associated antioxidant / polyphenol content will have had any effect.  527 
6.0 Conclusion 528 
This is the first study to examine the effects of inorganic nitrate supplementation in the form 529 
of concentrated beetroot juice ingestion on rewarming following a cold stimulus in individuals 530 
with cold sensitivity. Despite a physiologically meaningful rise in plasma nitrite 531 
concentrations, acute nitrate supplementation did not alter extremity rewarming, endothelial 532 
function, blood pressure, pain or thermal comfort and sensation. Although we cannot 533 
preclude the possibility that a chronic nitrate supplementation regime could improve 534 
extremity rewarming and microvascular function in cold sensitive individuals, acute nitrate 535 
supplementation does not appear to improve vascular function in this sub-clinical population 536 
following acute cold exposure.   537 
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